The ctDNA-based test first to be approved by FDA is for the detection of EGFR mutations in NSCLC patients to start treatment with EGFR-TKIs (Rijavec et al., 2019; Abdayem and Planchard, 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.